Asthma trigger

Last updated
Examples of asthma triggers Asthma triggers 2.PNG
Examples of asthma triggers

Asthma triggers are factors or stimuli that provoke the exacerbation of asthma symptoms or increase the degree of airflow disruption, which can lead to an asthma attack. [1] An asthma attack is characterized by an obstruction of the airway, hypersecretion of mucus and bronchoconstriction due to the contraction of smooth muscles around the respiratory tract. Its symptoms include a wide range of manifestations such as breathlessness, coughing, a tight chest and wheezing. [2]

Contents

An asthma attack is usually mediated by an inflammatory pathway, where a trigger such as an allergen could lead to a series of immune response mediated by various types of immune cells. [3]

Common triggers for asthma include allergens like pet dander, dust mites, pollens and molds. Other types of triggers like exercise, air pollutants, tobacco smoke, humidity, cold air, or certain medicines may also play a role in triggering asthma. [4] While it has been proposed that asthma triggers can be classified into three types: allergic triggers, environmental triggers and physical triggers, a universal categorization of asthma triggers has yet to be done. [4] Other studies have also classified asthma triggers into psychological factors, air pollutants, physical activity, allergens and infection. [5]

Asthma is an extremely common chronic disease affecting over 26 million people and 7 million children in the US. [3] Recognizing the trigger for asthma and avoiding it can be a simple yet effective way to deal with the disease and avoid an asthma attack. [6] Although a cure for asthma is yet to be invented, various treatment methods are available for both long-term control and immediate relieve of an asthma attack. [7]

Pathophysiology

Figure showing the physiological changes in the respiratory tract during an asthma attack upon contact with a trigger Asthma attack-illustration NIH.jpg
Figure showing the physiological changes in the respiratory tract during an asthma attack upon contact with a trigger

The pathophysiology for asthma mainly involves the inflammatory pathway, associated with several types of immune cells in the body, mainly T helper 2 cells (Th2 cells), B cells and mast cells. In a nut shell, as a stimulus, such as an allergen comes into contact with an asthma patient, it activates various types of immune cells leading to an inflammatory response, causing bronchial hyperresponsiveness, bronchoconstriction, excessive mucus secretion, airflow obstruction and an asthma attack. [3] A more detail rundown of the process is provided below.

First, during the sensitization phase, where T cells interact with dendritic cells, the dendritic cells will present a specific antigen from the allergen to Th2 cells, leading to their development. [8] Afterward, the activated Th2 cells would release interleukine-4, a type of cytokine to promote B cells, another type of immune cell to differentiate intoallergen-specific memory B cells and plasma cells. [9] The plasma cells will then extensively produce allergen-specific IgE antibodies, which are captured by a type of receptor, FceRI, on the mast cells. [9]

Mast cells are immune cells usually located at tissues exposed to the environment, such as the skin, respiratory tract mucosa and digestive tract mucosa. [10] They are equipped with preformed granules loaded with vasoactive amines and proteases. [11] As the FceRI receptors on mast cells capture the IgE antibodies produced by Th2 cells, they become sensitive to the specific allergen.

Diagram showing the typical pathway for an allergic response leading to asthma The Allergy Pathway.jpg
Diagram showing the typical pathway for an allergic response leading to asthma

Due to this, the mast cells will be activated when they are exposed to the specific allergen. As an allergen binds to the IgE antibodies on the mast cell surface, clustering and cross-link formation of FceRI takes place. [12] [10] This leads to the recruitment and activation of several tyrosine kinases, a type of enzyme that phosphorylates protein. [13] Consequently, these kinase activation contributes to intracellular Ca2+ influx after a series of reaction. The Ca2+ level surge results in cytoskeletal rearrangement, allowing exocytosis and degranulation of intracellular granules, thus releasing vasoactive amines and proteases. [14] These vasoactive amines such as histamine, heparin and serotonin released from the mast cell granules cause vasodilation, increased vascular permeability, smooth muscle contraction and increased mucus secretion.[ citation needed ] Mast cells degranulation also results in the release of eosinophil chemotactic factors and neutrophil chemotactic factors. These factors attract eosinophils and neutrophils from the body respectively, which can intensify the inflammation response. [15] Moreover, the elevated Ca2+ level also leads to arachidonic acid enzymatic pathway activation, contributing to the release of lipid mediators. [16] These lipid mediators, particularly prostaglandins and leukotrienes elicit vasodilation, increased vascular permeability and smooth muscle contraction. [17] Moreover, the increase in Ca2+ level also leads to activation of certain transcription factors which induces pro-inflammatory cytokines transcription. [18] These pro-inflammatory cytokines such as TNF, Interleukin-1 and Interleukin-8 lead to acute inflammation and leukocyte recruitment. [19]

Examples of asthma triggers

Microscopic image of a house dust mite, which can trigger asthma. House Dust Mite.jpg
Microscopic image of a house dust mite, which can trigger asthma.

Allergic triggers

Allergic triggers are factors or chemicals that could induce airway sensitization, inflammation, bronchospasm and other asthmatic symptoms. [20]

Allergens are the most common trigger for allergic asthma. Examples of such triggers of asthma include naturally occurring aeroallergens like house dust mites, animal feces and pollen. [21] Pets, molds and pests are also potential triggers. [22] When an asthma patient inhales or come into contact withsuch allergen, mast cells in the airway tract releases vasoactive amines and proteases. This leads to a release of cytokines and mediates a broad range of inflammatory and allergic responses. [19]

Environmental triggers

In addition to allergens, studies have revealed that environmental factors may also increase the risk of triggering an asthma attack. [21] [23] Examples of these factors include respiratory tract viral infections, [24] exposure to air pollutants such as ozone [25] or a change in lifestyle that involves a decrease in exposure to microbes and their products like endotoxin. [26] Although its mechanism of action is still unknown, an in vivo study [21] has demonstrated that these environmental factors lead to the accumulation of neutrophil extracellular traps (NET) releasing neutrophils in the lungs. This increased release of NETs have been found to be associated with asthmatic symptoms such as mucus hypersecretion. [27]

Another environmental risk factor is exposure to formaldehyde. [28] Formaldehyde itself is a chemical that can cause irritation to the respiratory tract. In addition, it may react with macromolecules such as albumin which can induce the production of igE antibodies which can bind to mast cells and lead to hyperresponsiveness of the respiratory tract. [28]

Exercise

Exercise induced asthma is common in most asthma patients. [29] Although the mechanism for such a phenomenon is still unclear, researchers have proposed that as the body gasps for more oxygen during exercise, more cold and dry air is inhaled. The passage of this cold and dry air causes a loss of moisture from the mucosal membrane of the respiratory tract. The osmolarity changes brought by such action can lead to an increased release of proinflammatory mediators such as cytokines, leading to a hypersensitivity of the airway. [30] [31] Cooling of the respiratory tract may also activate cholinergic receptors, which can induce bronchoconstriction and mucus secretion, further narrowing the airway. [32] Swimmers with asthma may also inhale an excess amount of contaminated and irritating air with compound derived from chlorine gas, this can increase the risk of an asthma attack. [33]

Medications

Image of aspirin which can be a trigger for asthma in some patients. Bayer Aspirin Pills.jpg
Image of aspirin which can be a trigger for asthma in some patients.

Aspirin induced asthma, or aspirin-exacerbated respiratory disease, refers to situations where the use of aspirin worsen the asthma conditions. [34] Other non-steroidal anti-inflammatory drugs (NSAIDs) that inhibits the enzyme, cyclooxygenase-1, may also lead to an asthma attack.

After the inhibition of cyclooxygenase-1 enzyme by the NSAIDs, an accumulation of arachidonic acid will be resulted. This, in turn, would increase the production of leukotrienes. Leukotrienes is an inflammatory mediator. The accumulation of proinflammatory leukotrienes would overstimulate the cysteinyl leukotriene receptors in the respiratory system, leading to bronchoconstriction and the over-secretion of mucus, thus blocking the airway. [34]

Beta-blocker, or beta-adrenergic antagonists, may also induce bronchial constriction and block the action of other beta-receptor targeted asthmatic drugs, leading to a worsening asthma condition. [35] Therefore, asthma patients should be cautious and inform their physicians of their asthma conditions. [36]

Occupational asthma triggers

Occupational asthma refers to a type of asthma that is resulted from repeated exposure to an agent that causes or exacerbates asthma in a workplace. [37] Although the primary cause for occupational asthma varies from situation to situation, common agents such as metal, diesel, cleaning agents, dimethylsulphate, diisocyanates, latex, persulfate, aldehydes, isocyanates, wood dusts and flour should be handled with great care. [38] [39] [40]

Tobacco smoke

Both first-hand and second-hand tobacco smoke can be a trigger for asthma attack. [41] It may worsen the condition of asthma as it is an irritant and induces bronchoconstriction. [42]

Psychological triggers

Studies have also indicated that psychological stress may be associated with a higher chance of asthma attack. [5] Patients with psychological stress are found to have a reduced awareness of controlling asthma and a less desirable physical health. [5] [43]

Symptom

One of the clinical asthmatic symptoms is shortness of breath due to narrowing of the respiratory tract, caused by mucus plug formation and bronchoconstriction as smooth muscles contract. [44] Another typical symptom is wheezing. During expiration, turbulent airflow crushes the narrowed respiratory tract, leading to a wheezing sound. [45] Moreover, the increased mucus secretion may not be limited to the respiratory tract, and other symptoms such as watery eyes and rhinitis are also common. [45] Furthermore, increased vasodilation and vascular permeability may result in angioedema, the swelling of the skin, and hives. [46] In severe complications, as ventilation is impaired, acute respiratory failure may occur due to the inadequate amount of oxygen in the circulatory system. [47] Another life-threatening condition is pneumothorax, the collapse of the lungs due to hyperinflation. [48]

Avoidance

Understanding the specific asthma triggers for a patient and avoiding them can be a simple way for preventing an asthma attack. [41] Regularly washing beddings, quitting smoking, doing pest controls, keeping a sensitized living environment, removing stagnant water, avoiding products with potential irritants, etc., can be effective in avoiding an asthma attack. [41]

Education about asthma triggers should be done by physicians to help patients understand what activities or materials should be avoided. Reduction of exposure to asthma triggers should be done by asthmatic patient as well. [4] Parents of asthmatic children should also be cautious of common asthma triggers in order to reduce risks of an asthma attack. [22]

Treatment

Image of an asthma medication inhaler which can be used to administer the medicine through the pulmonary route Asthma Medication Inhaler.JPG
Image of an asthma medication inhaler which can be used to administer the medicine through the pulmonary route

Quick-relief medicine

Quick-relief medicine are used for treating an acute asthma attack. The first line of medicine for treating this situation is short-term beta-2-adrenoreceptor agonists, which are drugs that can stimulate the beta-2 adrenergic receptors. They are bronchodilators and can effectively relieve the symptoms by clearing the airway. Examples include albuterol and levalbuterol. [7] Commonly they are used with a portable inhaler which allows the patient to administer the medicine at once during an attack.

Another common medicine for an acute attack is anticholinergic drugs such as ipratropium and tiotropium, which are also bronchodilators. [7] They work by blocking off the cholinergic receptors and reduces mucus secretion and bronchoconstriction. [7]

Another type of treatment for acute asthma attack is immunosuppressive drugs like corticosteroids, which can also alleviate an asthmatic response. [49] Examples include prednisone and methyl prednisone which are usually administered orally or intravenously for treating an acute situation. [7] However, note that long term use of corticosteroids may lead to severe side effects.

Long-term control

Continuous and long-term use of certain medicines can help reduce the risk of an asthma attack and keep the disease under control.

Chemical structure of prednisolone, a corticosteroid that can help relief an acute asthma attack Prednisolone.svg
Chemical structure of prednisolone, a corticosteroid that can help relief an acute asthma attack

Long term use of certain types of corticosteroids, such as fluticasone propionate may be administered through the pulmonary route to reduce the risk of an asthma attack. [50]

Oral use of leukotriene receptor antagonist such as Zafirlukast may also be used as a long term control for asthma in addition to corticosteroids. [51] [52]

Moreover, another option is the use of cromolyn sodium, which can prevent an asthma attack by halting Ca2+ influx, thus preventing mast cell degranulation and subsequent asthmatic complications [53]

Other than drugs, an alternative treatment method is de-sensitization, which involves exposure to a well-controlled, small and increasing amounts of specific allergen over a long duration of time. [54] The rationale is to trigger antigen competition by the development of allergen-specific IgG antibodies, which can reduce to risk of an allergic response. [54]

Long-acting beta-agonists such as salmetrol had been used in combination with corticosteroids to control asthma symptoms. They are drugs that can stimulate the beta-2 adrenergic receptors and mediate a bronchodilation effect for over 12 hours. However, a recent study in 2010 has found that this treatment method could increase the risk of asthma-related deaths and intubations. [55] The Food and Drug Administration (FDA) is also recommending the discontinuation of the drug if asthma control has been achieved. [56]

Related Research Articles

<span class="mw-page-title-main">Asthma</span> Long-term inflammatory disease of the airways of the lungs

Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. These may occur a few times a day or a few times per week. Depending on the person, asthma symptoms may become worse at night or with exercise.

<span class="mw-page-title-main">Allergy</span> Immune system response to a substance that most people tolerate well

Allergies, also known as allergic diseases, are various conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. Symptoms may include red eyes, an itchy rash, sneezing, coughing, a runny nose, shortness of breath, or swelling. Note that food intolerances and food poisoning are separate conditions.

<span class="mw-page-title-main">Eosinophil</span> Variety of white blood cells

Eosinophils, sometimes called eosinophiles or, less commonly, acidophils, are a variety of white blood cells and one of the immune system components responsible for combating multicellular parasites and certain infections in vertebrates. Along with mast cells and basophils, they also control mechanisms associated with allergy and asthma. They are granulocytes that develop during hematopoiesis in the bone marrow before migrating into blood, after which they are terminally differentiated and do not multiply.

<span class="mw-page-title-main">Immunoglobulin E</span> Immunoglobulin E (IgE) Antibody

Immunoglobulin E (IgE) is a type of antibody that has been found only in mammals. IgE is synthesised by plasma cells. Monomers of IgE consist of two heavy chains and two light chains, with the ε chain containing four Ig-like constant domains (Cε1–Cε4). IgE is thought to be an important part of the immune response against infection by certain parasitic worms, including Schistosoma mansoni, Trichinella spiralis, and Fasciola hepatica. IgE is also utilized during immune defense against certain protozoan parasites such as Plasmodium falciparum. IgE may have evolved as a defense to protect against venoms.

<span class="mw-page-title-main">Rhinitis</span> Irritation and inflammation of the mucous membrane inside the nose

Rhinitis, also known as coryza, is irritation and inflammation of the mucous membrane inside the nose. Common symptoms are a stuffy nose, runny nose, sneezing, and post-nasal drip.

<span class="mw-page-title-main">Leukotriene</span> Class of inflammation mediator molecules

Leukotrienes are a family of eicosanoid inflammatory mediators produced in leukocytes by the oxidation of arachidonic acid (AA) and the essential fatty acid eicosapentaenoic acid (EPA) by the enzyme arachidonate 5-lipoxygenase.

<span class="mw-page-title-main">Cromoglicic acid</span> Chemical compound

Cromoglicic acid (INN)—also referred to as cromolyn (USAN), cromoglycate, or cromoglicate—is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells.

<span class="mw-page-title-main">Aspirin-exacerbated respiratory disease</span> Chronic inflammatory disease affecting the sinuses and lungs

Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Compared to aspirin tolerant patients, AERD patients' asthma and nasal polyps are generally more severe. Reduction or loss of the ability to smell is extremely common, occurring in more than 90% of people with the disease. AERD most commonly begins in early- to mid-adulthood and has no known cure. While NSAID intolerance is a defining feature of AERD, avoidance of NSAIDs does not affect the onset, development or perennial nature of the disease.

<span class="mw-page-title-main">Bronchoconstriction</span> Constriction of the terminal airways in the lungs

Bronchoconstriction is the constriction of the airways in the lungs due to the tightening of surrounding smooth muscle, with consequent coughing, wheezing, and shortness of breath.

Acute severe asthma, also known as status asthmaticus, is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators (inhalers) and corticosteroids. Asthma is caused by multiple genes, some having protective effect, with each gene having its own tendency to be influenced by the environment although a genetic link leading to acute severe asthma is still unknown. Symptoms include chest tightness, rapidly progressive dyspnea, dry cough, use of accessory respiratory muscles, fast and/or labored breathing, and extreme wheezing. It is a life-threatening episode of airway obstruction and is considered a medical emergency. Complications include cardiac and/or respiratory arrest. The increasing prevalence of atopy and asthma remains unexplained but may be due to infection with respiratory viruses.

Exercise-induced bronchoconstriction (EIB) occurs when the airways narrow as a result of exercise. This condition has been referred to as exercise-induced asthma (EIA); however, this term is no longer preferred. While exercise does not cause asthma, it is frequently an asthma trigger.

<span class="mw-page-title-main">Allergic bronchopulmonary aspergillosis</span> Medical condition

Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterised by an exaggerated response of the immune system to the fungus Aspergillus. It occurs most often in people with asthma or cystic fibrosis. Aspergillus spores are ubiquitous in soil and are commonly found in the sputum of healthy individuals. A. fumigatus is responsible for a spectrum of lung diseases known as aspergilloses.

An antileukotriene, also known as leukotriene modifier and leukotriene receptor antagonist, is a medication which functions as a leukotriene-related enzyme inhibitor or leukotriene receptor antagonist and consequently opposes the function of these inflammatory mediators; leukotrienes are produced by the immune system and serve to promote bronchoconstriction, inflammation, microvascular permeability, and mucus secretion in asthma and COPD. Leukotriene receptor antagonists are sometimes colloquially referred to as leukasts.

<span class="mw-page-title-main">Cysteinyl leukotriene receptor 1</span> Protein-coding gene in humans

Cysteinyl leukotriene receptor 1, also termed CYSLTR1, is a receptor for cysteinyl leukotrienes (LT). CYSLTR1, by binding these cysteinyl LTs contributes to mediating various allergic and hypersensitivity reactions in humans as well as models of the reactions in other animals.

<span class="mw-page-title-main">Thymic stromal lymphopoietin</span> Cytokine, alarmin, and growth factor.

Thymic stromal lymphopoietin (TSLP) is an interleukin (IL)-2-like cytokine, alarmin, and growth factor involved in numerous physiological and pathological processes, primarily those of the immune system. It shares a common ancestor with IL-7.

<span class="mw-page-title-main">Pathophysiology of asthma</span> Medical condition

Asthma is a common pulmonary condition defined by chronic inflammation of respiratory tubes, tightening of respiratory smooth muscle, and episodes of bronchoconstriction. The Centers for Disease Control and Prevention estimate that 1 in 11 children and 1 in 12 adults have asthma in the United States of America. According to the World Health Organization, asthma affects 235 million people worldwide. There are two major categories of asthma: allergic and non-allergic. The focus of this article will be allergic asthma. In both cases, bronchoconstriction is prominent.

Alcohol-induced respiratory reactions, also termed alcohol-induced asthma and alcohol-induced respiratory symptoms, are increasingly recognized as a pathological bronchoconstriction response to the consumption of alcohol that afflicts many people with a "classical" form of asthma, the airway constriction disease evoked by the inhalation of allergens. Alcohol-induced respiratory reactions reflect the operation of different and often racially related mechanisms that differ from those of classical, allergen-induced asthma.

Cysteinyl-leukotriene type 1 receptor antagonists Class of drugs that hinder the action of leukotriene

Cysteinyl-leukotriene type 1 receptor antagonists, also known as CysLT1 antagonists, are a class of drugs that hinder the action of leukotriene by binding to the receptor with antagonistic action without having an agonistic effect. These drugs are used to treat asthma, relieve individuals of seasonal allergies rhinitis and prevention of exercise-induced bronchoconstriction. There are currently three different types of drugs within the CysLT1 family, zafirlukast which was first on the market being released in 1996, montelukast which was released in 1998 and pranlukast which was released in 2007.

Asthma phenotyping and endotyping is a novel approach to asthma classification inspired by precision medicine. It seeks to separate the clinical presentations or clusters of signs and symptoms of asthma, known as asthma phenotypes, from their underlying etiologies or causes, known as asthma endotypes.

Anti-allergic agents are medications used to treat allergic reactions. Anti-allergic agents have existed since 3000 B.C in countries such as China and Egypt. It was not until 1933 when antihistamines, the first type of anti-allergic agents, were developed. Common allergic diseases include allergic rhinitis, allergic asthma and atopic dermatitis with varying symptoms, including runny nose, watery eyes, itchiness, coughing, and shortness of breath. More than one-third of the world's population is currently being affected by one or more allergic conditions.

References

  1. ↑ "Trigger", McGraw-Hill Concise Dictionary of Modern Medicine, retrieved 2022-03-29
  2. ↑ British Thoracic Society; Scottish Intercollegiate Guidelines Network (2014). "British guideline on the management of asthma". Thorax. 69 (Suppl 1): 1–192. ISSN   1468-3296. PMID   25323740.
  3. 1 2 3 Morris. M, MD, FACP, FCCP (2021-05-03). "Asthma: Practice Essentials, Background, Anatomy". Medscape.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. 1 2 3 Vernon, Margaret K.; Wiklund, Ingela; Bell, Jill A.; Dale, Peter; Chapman, Kenneth R. (2012-11-19). "What Do We Know about Asthma Triggers? A Review of the Literature". Journal of Asthma. 49 (10): 991–998. doi:10.3109/02770903.2012.738268. ISSN   0277-0903. PMID   23574397. S2CID   38294258.
  5. 1 2 3 Ritz, Thomas; Steptoe, Andrew; Bobb, Carol; Harris, Alexander H. S.; Edwards, Martin (2006). "The Asthma Trigger Inventory: Validation of a Questionnaire for Perceived Triggers of Asthma". Psychosomatic Medicine. 68 (6): 956–965. doi:10.1097/01.psy.0000248898.59557.74. ISSN   0033-3174. PMID   17132841. S2CID   31788889.
  6. ↑ Viswam, Darsana; Mansur, Adel H. (2020). "Mode of onset and triggers of severe asthma". Annals of Allergy, Asthma & Immunology. 128 (4): 466–467. doi:10.1016/j.anai.2022.01.006. ISSN   1081-1206. PMID   35031415. S2CID   245916683.
  7. 1 2 3 4 5 Bissell, Karen; Ellwood, Philippa; Ellwood, Eamon; Chiang, Chen-Yuan; Marks, Guy; El Sony, Asma; Asher, Innes; Billo, Nils; Perrin, Christophe (2019-02-19). "Essential Medicines at the National Level: The Global Asthma Network's Essential Asthma Medicines Survey 2014". International Journal of Environmental Research and Public Health. 16 (4): 605. doi: 10.3390/ijerph16040605 . ISSN   1660-4601. PMC   6406388 . PMID   30791442.
  8. ↑ Humeniuk, Piotr; Dubiela, Pawel; Hoffmann-Sommergruber, Karin (2017-07-11). "Dendritic Cells and Their Role in Allergy: Uptake, Proteolytic Processing and Presentation of Allergens". International Journal of Molecular Sciences. 18 (7): 1491. doi: 10.3390/ijms18071491 . ISSN   1422-0067. PMC   5535981 . PMID   28696399.
  9. 1 2 Saunders, Sean P.; Ma, Erica G. M.; Aranda, Carlos J.; Curotto de Lafaille, Maria A. (2019-04-26). "Non-classical B Cell Memory of Allergic IgE Responses". Frontiers in Immunology. 10: 715. doi: 10.3389/fimmu.2019.00715 . ISSN   1664-3224. PMC   6498404 . PMID   31105687.
  10. 1 2 Holgate, Stephen T (2013). "Mechanisms of Asthma and Implications for Its Prevention and Treatment: A Personal Journey". Allergy, Asthma & Immunology Research. 5 (6): 343–347. doi:10.4168/aair.2013.5.6.343. ISSN   2092-7355. PMC   3810539 . PMID   24179679.
  11. ↑ Bradding, P; Feather, I H; Howarth, P H; Mueller, R; Roberts, J A; Britten, K; Bews, J P; Hunt, T C; Okayama, Y; Heusser, C H (1992-11-01). "Interleukin 4 is localized to and released by human mast cells". Journal of Experimental Medicine. 176 (5): 1381–1386. doi:10.1084/jem.176.5.1381. ISSN   0022-1007. PMC   2119427 . PMID   1402683. S2CID   7033172.
  12. ↑ Beasley, Richard; Roche, William R.; Roberts, J. Alan; Holgate, Stephen T. (1989). "Cellular Events in the Bronchi in Mild Asthma and after Bronchial Provocation". American Review of Respiratory Disease. 139 (3): 806–817. doi:10.1164/ajrccm/139.3.806. ISSN   0003-0805. PMID   2923380.
  13. ↑ Gilfillan, Alasdair M.; Rivera, Juan (2009). "The tyrosine kinase network regulating mast cell activation". Immunological Reviews. 228 (1): 149–169. doi:10.1111/j.1600-065x.2008.00742.x. ISSN   0105-2896. PMC   2669301 . PMID   19290926.
  14. ↑ Klein, Ofir; Sagi-Eisenberg, Ronit (2019-03-18). "Anaphylactic Degranulation of Mast Cells: Focus on Compound Exocytosis". Journal of Immunology Research. 2019: 1–12. doi: 10.1155/2019/9542656 . ISSN   2314-8861. PMC   6442490 . PMID   31011586.
  15. ↑ Goetzl, E J; Austen, K F (1976-12-01). "Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis". Journal of Experimental Medicine. 144 (6): 1424–1437. doi:10.1084/jem.144.6.1424. ISSN   0022-1007. PMC   2190483 . PMID   1003098.
  16. ↑ Ong, W.-Y.; Farooqui, T.; Farooqui, A.A. (2010-09-01). "Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions". Current Medicinal Chemistry. 17 (25): 2746–2763. doi:10.2174/092986710791859289. ISSN   0929-8673. PMID   20586719.
  17. ↑ Funk, Colin D. (2001-11-30). "Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology". Science. 294 (5548): 1871–1875. Bibcode:2001Sci...294.1871F. doi:10.1126/science.294.5548.1871. ISSN   0036-8075. PMID   11729303.
  18. ↑ Cargnello, Marie; Roux, Philippe P. (2011). "Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases". Microbiology and Molecular Biology Reviews. 75 (1): 50–83. doi:10.1128/mmbr.00031-10. ISSN   1092-2172. PMC   3063353 . PMID   21372320.
  19. 1 2 Zhang, Jun-Ming; An, Jianxiong (2007). "Cytokines, Inflammation, and Pain". International Anesthesiology Clinics. 45 (2): 27–37. doi:10.1097/aia.0b013e318034194e. ISSN   0020-5907. PMC   2785020 . PMID   17426506.
  20. ↑ D'Amato, M; Cecchi, L; Annesi-Maesano, I; D'Amato, G (2018-04-16). "News on Climate Change, Air Pollution, and Allergic Triggers of Asthma". Journal of Investigational Allergology and Clinical Immunology. 28 (2): 91–97. doi: 10.18176/jiaci.0228 . ISSN   1018-9068. PMID   29345235.
  21. 1 2 3 Radermecker, Coraline; Sabatel, Catherine; Vanwinge, Céline; Ruscitti, Cecilia; Maréchal, Pauline; Perin, Fabienne; Schyns, Joey; Rocks, Natacha; Toussaint, Marie; Cataldo, Didier; Johnston, Sebastian L (2019). "Locally instructed CXCR4hi neutrophils trigger environment-driven allergic asthma through the release of neutrophil extracellular traps". Nature Immunology. 20 (11): 1444–1455. doi:10.1038/s41590-019-0496-9. ISSN   1529-2908. PMC   6859073 . PMID   31591573.
  22. 1 2 Morgan, Wayne J.; Crain, Ellen F.; Gruchalla, Rebecca S.; O'Connor, George T.; Kattan, Meyer; Evans, Richard; Stout, James; Malindzak, George; Smartt, Ernestine; Plaut, Marshall; Walter, Michelle (2004-09-09). "Results of a Home-Based Environmental Intervention among Urban Children with Asthma". New England Journal of Medicine. 351 (11): 1068–1080. doi: 10.1056/nejmoa032097 . ISSN   0028-4793. PMID   15356304.
  23. ↑ Eder, Waltraud; Ege, Markus J.; von Mutius, Erika (2006-11-23). "The Asthma Epidemic". New England Journal of Medicine. 355 (21): 2226–2235. doi:10.1056/NEJMra054308. ISSN   0028-4793. PMID   17124020.
  24. ↑ Busse, William W; Lemanske, Robert F; Gern, James E (2010). "Role of viral respiratory infections in asthma and asthma exacerbations". The Lancet. 376 (9743): 826–834. doi:10.1016/S0140-6736(10)61380-3. PMC   2972660 . PMID   20816549.
  25. ↑ Peden, David B. (2005). "The epidemiology and genetics of asthma risk associated with air pollution". Journal of Allergy and Clinical Immunology. 115 (2): 213–219. doi:10.1016/j.jaci.2004.12.003. ISSN   0091-6749. PMID   15696070.
  26. ↑ Braun-Fahrländer, Charlotte; Riedler, Josef; Herz, Udo; Eder, Waltraud; Waser, Marco; Grize, Leticia; Maisch, Soyoun; Carr, David; Gerlach, Florian; Bufe, Albrecht; Lauener, Roger P. (2002-09-19). "Environmental Exposure to Endotoxin and Its Relation to Asthma in School-Age Children". New England Journal of Medicine. 347 (12): 869–877. doi: 10.1056/nejmoa020057 . ISSN   0028-4793. PMID   12239255.
  27. ↑ Liu, Ting; Wang, Fa-Ping; Wang, Geng; Mao, Hui (2017). "Role of Neutrophil Extracellular Traps in Asthma and Chronic Obstructive Pulmonary Disease". Chinese Medical Journal. 130 (6): 730–736. doi: 10.4103/0366-6999.201608 . ISSN   0366-6999. PMC   5358425 . PMID   28303858.
  28. 1 2 McGwin, Gerald; Lienert, Jeffrey; Kennedy, John I. (2010). "Formaldehyde Exposure and Asthma in Children: A Systematic Review". Environmental Health Perspectives. 118 (3): 313–317. doi:10.1289/ehp.0901143. ISSN   0091-6765. PMC   2854756 . PMID   20064771.
  29. ↑ Crapo, R. O.; Casaburi, R.; Coates, A. L.; Enright, P. L.; Hankinson, J. L.; Irvin, C. G.; MacIntyre, N. R.; McKay, R. T.; Wanger, J. S.; Anderson, S. D.; Cockcroft, D. W.; Fish, J. E.; Sterk, P. J. (2000). "Guidelines for Methacholine and Exercise Challenge Testing—1999". American Journal of Respiratory and Critical Care Medicine. 161 (1): 309–329. doi:10.1164/ajrccm.161.1.ats11-99. ISSN   1073-449X. PMID   10619836.
  30. ↑ Raddeley, R (1988). "Surgical management of morbid obesity. W. O. Griffin Jr. 150 × 230 mm. Pp. 284. Illustrated. 1987. New York: Marcel Dekker Inc. $95.50". British Journal of Surgery. 75 (5): 503. doi:10.1002/bjs.1800750554. ISSN   0007-1323.
  31. ↑ Anderson, Sandra D.; Daviskas, Evangelia (2000). "The mechanism of exercise-induced asthma is …". Journal of Allergy and Clinical Immunology. 106 (3): 453–459. doi: 10.1067/mai.2000.109822 . ISSN   0091-6749. PMID   10984363.
  32. ↑ McFADDEN, E. R.; NELSON, JO ANN; SKOWRONSKI, M. E.; LENNER, K. A. (1999). "Thermally Induced Asthma and Airway Drying". American Journal of Respiratory and Critical Care Medicine. 160 (1): 221–226. doi:10.1164/ajrccm.160.1.9810055. ISSN   1073-449X. PMID   10390404.
  33. ↑ Thickett, K.M.; McCoach, J.S.; Gerber, J.M.; Sadhra, S.; Burge, P.S. (2002-05-01). "Occupational asthma caused by chloramines in indoor swimming-pool air". European Respiratory Journal. 19 (5): 827–832. doi: 10.1183/09031936.02.00232802 . ISSN   0903-1936. PMID   12030720. S2CID   5788935.
  34. 1 2 Szczeklik, Andrew; Stevenson, Donald D. (2003). "Aspirin-induced asthma: Advances in pathogenesis, diagnosis, and management". Journal of Allergy and Clinical Immunology. 111 (5): 913–921. doi:10.1067/mai.2003.1487. PMID   12743549.
  35. ↑ Morales, Daniel R.; Lipworth, Brian J.; Donnan, Peter T.; Jackson, Cathy; Guthrie, Bruce (2017). "Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study". BMC Medicine. 15 (1): 18. doi: 10.1186/s12916-017-0781-0 . ISSN   1741-7015. PMC   5270217 . PMID   28126029.
  36. ↑ "Medicines Can Trigger Asthma". Asthma and allergy foundation of america. 2018. Retrieved 2022-03-29.
  37. ↑ Tarlo, Susan M.; Lemiere, Catherine (2014-02-13). "Occupational Asthma". New England Journal of Medicine. 370 (7): 640–649. doi:10.1056/nejmra1301758. ISSN   0028-4793. PMID   24521110.
  38. ↑ "Handling fish can cause occupational asthma". Food and Chemical Toxicology. 35 (9): 930. 1997. doi:10.1016/s0278-6915(97)90051-x. ISSN   0278-6915.
  39. ↑ Baur, Xaver; Bakehe, Prudence (2014). "Allergens causing occupational asthma: an evidence-based evaluation of the literature". International Archives of Occupational and Environmental Health. 87 (4): 339–363. Bibcode:2014IAOEH..87..339B. doi:10.1007/s00420-013-0866-9. ISSN   0340-0131. PMID   23595938. S2CID   38640302.
  40. ↑ Labrecque, Manon (2012). "Irritant-induced asthma". Current Opinion in Allergy & Clinical Immunology. 12 (2): 140–144. doi:10.1097/aci.0b013e32835143b8. ISSN   1528-4050. PMID   22327170. S2CID   28763190.
  41. 1 2 3 "Asthma and Secondhand Smoke". Centers for Disease Control and Prevention. 2022-02-11. Retrieved 2022-03-29.
  42. ↑ Pietinalho, A.; Pelkonen, A.; Rytilä, P. (2009-10-12). "Linkage between smoking and asthma". Allergy. 64 (12): 1722–1727. doi:10.1111/j.1398-9995.2009.02208.x. ISSN   0105-4538. PMID   19832738. S2CID   40233991.
  43. ↑ Van Lieshout, Ryan J; MacQueen, Glenda (2008). "Psychological Factors in Asthma". Allergy, Asthma & Clinical Immunology. 4 (1): 12–28. doi: 10.1186/1710-1492-4-1-12 . ISSN   1710-1492. PMC   2869336 . PMID   20525122.
  44. ↑ Frontiers Production, Office (2022-03-23). "Erratum: Mechanisms of Particles in Sensitization, Effector Function and Therapy of Allergic Disease". Frontiers in Immunology. 13: 891445. doi: 10.3389/fimmu.2022.891445 . ISSN   1664-3224. PMC   8985158 . PMID   35401505.
  45. 1 2 Parker, R. (2007-08-01). "Gibson P. Evidence-based respiratory medicine. Oxford: Blackwell BMJ, 2005". Evidence-Based Medicine. 12 (4): 125. doi: 10.1136/ebm.12.4.125 . ISSN   1356-5524. S2CID   71255770.
  46. ↑ Bernstein, Jonathan A; Moellman, Joseph (2012-11-06). "Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema". International Journal of Emergency Medicine. 5 (1): 39. doi: 10.1186/1865-1380-5-39 . ISSN   1865-1380. PMC   3518251 . PMID   23131076. S2CID   9039857.
  47. ↑ Smyth, Melinda (2005). "Acute Respiratory Failure: Part 2. Failure of Ventilation". American Journal of Nursing. 105 (6): 72AA–72DD. doi:10.1097/00000446-200506000-00040. ISSN   0002-936X.
  48. ↑ E, Yiannakopoulou (2018-12-21). "Pneumothorax, pneumomediastinum, subcutaneous emphysema: serious complications of asthma". Archives of Asthma, Allergy and Immunology. 2 (1): 016–017. doi: 10.29328/journal.aaai.1001014 . ISSN   2639-3182. S2CID   80725017.
  49. ↑ Djukanović, Ratko; Wilson, John W.; Britten, Karen M.; Wilson, Susan J.; Walls, Andrew F.; Roche, William R.; Howarth, Peter H.; Holgate, Stephen T. (1992). "Effect of an Inhaled Corticosteroid on Airway Inflammation and Symptoms in Asthma". American Review of Respiratory Disease. 145 (3): 669–674. doi:10.1164/ajrccm/145.3.669. ISSN   0003-0805. PMID   1546849.
  50. ↑ Harrison, TW; Oborne, J; Newton, S; Tattersfield, AE (2004). "Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial". The Lancet. 363 (9405): 271–275. doi:10.1016/s0140-6736(03)15384-6. ISSN   0140-6736. PMID   14751699. S2CID   28581643.
  51. ↑ Choi, Jaehwa; Azmat, Chaudhary Ehtsham (2023), "Leukotriene Receptor Antagonists", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   32119332 , retrieved 2023-06-20
  52. ↑ "thuốc trị hen suyễn" . Retrieved 20 June 2023.
  53. ↑ Georgopoulos, Dimitris; Giulekas, Dimitris; Ilonidis, George; Sichletidis, Lazaws (1989). "Effect of Salbutamol, Ipratropium Bromide and Cromolyn Sodium on Prostaglandin F2α -Induced Bronchospasm". Chest. 96 (4): 809–814. doi:10.1378/chest.96.4.809. ISSN   0012-3692. PMID   2529105.
  54. 1 2 Krishna, M T; Huissoon, A P (2010-12-22). "Clinical immunology review series: an approach to desensitization". Clinical and Experimental Immunology. 163 (2): 131–146. doi:10.1111/j.1365-2249.2010.04296.x. ISSN   0009-9104. PMC   3043304 . PMID   21175592.
  55. ↑ Salpeter, Shelley R.; Wall, Andrew J.; Buckley, Nicholas S. (2010). "Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events". The American Journal of Medicine. 123 (4): 322–328.e2. doi:10.1016/j.amjmed.2009.07.035. PMID   20176343.
  56. ↑ Chowdhury, Badrul A.; Dal Pan, Gerald (2010). "The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma". New England Journal of Medicine. 362 (13): 1169–1171. doi: 10.1056/NEJMp1002074 . ISSN   0028-4793. PMID   20181964.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.